Mecapegfilgrastim

DRUG4 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Fudan University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital with Nanjing Medical University

Conditions

GC/GEJCMetastatic Breast CancerSmall Cell Lung CancerTriple-negative Breast Cancer

Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

RecruitingNCT05076682

Fudan UniversityTriple-negative Breast Cancer

Start: 2022-06-30End: 2027-03-31Target: 80Updated: 2025-12-03

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Active, not recruitingNCT05463601

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityMetastatic Breast Cancer

Start: 2022-08-01End: 2026-12-31Target: 132Updated: 2025-05-14

Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC

Not yet recruitingNCT06684158

The First Affiliated Hospital with Nanjing Medical UniversityGC/GEJC

Start: 2024-11-30End: 2027-12-01Target: 70Updated: 2024-11-12

Unknown Phase

Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis

Tianjin Medical University Cancer Institute and HospitalSmall Cell Lung Cancer

Start: 2019-11-10End: 2021-10-31Target: 93Updated: 2019-11-21

Related Papers

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.

2025-06-25

Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)

Cancer Research2024-05-02